TCGA-44-3398-01A-01R-1107-07
— · cohortA1
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortA1
- subtype
- cohortA1
- age_years
- 77
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.480
- ALLOGRAFT_REJECTION+0.420
- KRAS_SIGNALING_UP+0.420
- ANGIOGENESIS+0.390
- COAGULATION+0.380
- IL6_JAK_STAT3_SIGNALING+0.380
- INFLAMMATORY_RESPONSE+0.370
- COMPLEMENT+0.350
- OXIDATIVE_PHOSPHORYLATION+0.340
- HYPOXIA+0.320
Top 10 suppressed
- MYC_TARGETS_V2-0.620
- G2M_CHECKPOINT-0.580
- E2F_TARGETS-0.550
- MITOTIC_SPINDLE-0.550
- WNT_BETA_CATENIN_SIGNALING-0.510
- HEDGEHOG_SIGNALING-0.250
- MYC_TARGETS_V1-0.220
- SPERMATOGENESIS-0.220
- APICAL_SURFACE-0.190
- UNFOLDED_PROTEIN_RESPONSE-0.190
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-67-3772-01A-01R-0946-07 | — | cohortA1 | 0.921 |
| 2 | TCGA-97-8177-01A-11R-2287-07 | — | cohortA1 | 0.899 |
| 3 | TCGA-50-5045-01A-01R-1628-07 | — | cohortA1 | 0.875 |
| 4 | SRR8518396 | — | A | 0.872 |
| 5 | 185b401a-bdc4-46b9-b2a5-7a66938f28f2 | — | — | 0.856 |
| 6 | MDT-AP-2181 | Med | Medulloblastoma | 0.855 |
| 7 | TCGA-DQ-5630-01A-01R-1873-07 | — | — | 0.853 |
| 8 | TCGA-67-3773-01A-01R-0946-07 | — | cohortA1 | 0.849 |
| 9 | SRR8518286 | — | F | 0.848 |
| 10 | TCGA-49-4501-01A-01R-1206-07 | — | cohortA1 | 0.843 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 29 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.480 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.420 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.420 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.390 | Remibrutinib | — uncovered |
| COAGULATION | 0.380 | Binimetinib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.380 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.370 | Idelalisib | — uncovered |
| COMPLEMENT | 0.350 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.340 | Remibrutinib | — uncovered |
| HYPOXIA | 0.320 | Idelalisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.310 | Cobimetinib | — uncovered |
| IL2_STAT5_SIGNALING | 0.270 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.270 | Idelalisib | — uncovered |
| PROTEIN_SECRETION | 0.260 | Remibrutinib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.260 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.250 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.240 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.240 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.200 | Inavolisib | — uncovered |
| APOPTOSIS | 0.180 | Idelalisib | — uncovered |